Home › Companies › AKBA

Akebia Therapeutics, Inc.

AKBA Rare disease Lead: Approved 2 Biotech Distilled articles ↓

Hematology Ophthalmology Renal Respiratory Protein Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (14 active programs)

Vafseo

vadadustat

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase

Anemia Due to Chronic Kidney Disease Approved oral

Auryxia

ferric citrate

Hyperphosphatemia Approved oral
Iron Deficiency Anemia Approved oral

praliciguat

Small Molecule Target: sGC, soluble guanylate cyclase

Focal Segmental Glomerulosclerosis Phase 2 oral Cyclerion Therapeutics
Undisclosed indication

AKB-097

Protein Target: C3d, Factor H

AKB-9090

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase, HIF

Cardiac Surgery-Related Acute Kidney Injury Phase 1
Acute Respiratory Distress Syndrome Preclinical
Undisclosed indication

AKB-10108

Small Molecule Target: HIF-PH, HIF prolyl hydroxylase, HIF

Retinopathy of Prematurity Preclinical
Undisclosed indication

Biotech Distilled coverage (2)

2026-05-08 UPDATE: Akebia Therapeutics (AKBA) - The Receipts Arrive 🔒 Paid
2026-03-04 Akebia (AKBA): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.